Leber congenital amaurosis

Leber congenital amaurosis
Name	Leber congenital amaurosis
Field	Ophthalmology, Medical genetics
Symptoms	Severe vision loss from birth, nystagmus, sluggish pupils
Complications	Cataract, Keratoconus
Onset	Birth
Duration	Lifelong
Causes	Mutations in at least 25 genes (e.g., RPE65, CEP290, GUCY2D)
Risks	Genetic inheritance (Autosomal recessive)
Diagnosis	Electroretinography, Genetic testing, Fundus examination
Differential	Achromatopsia, Retinopathy of prematurity, Optic nerve hypoplasia
Prevention	Genetic counseling
Treatment	Gene therapy (Voretigene neparvovec), Low vision aids
Prognosis	Stable but severe impairment; treatment can improve function
Frequency	~1 in 40,000 to 1 in 100,000 newborns

Leber congenital amaurosis is a rare, inherited retinal dystrophy that represents one of the most severe forms of Childhood blindness. It is characterized by profound visual impairment or blindness detectable in the first few months of life. The condition is named for the German ophthalmologist Theodor Leber, who first described it in the 19th century. As a genetically heterogeneous disorder, it involves dysfunction of the photoreceptor cells or the Retinal pigment epithelium.

Signs and symptoms

The hallmark clinical presentation includes severe vision loss or non-responsiveness to visual stimuli in infancy, often accompanied by roving eye movements known as Nystagmus. Infants typically exhibit the Oculodigital sign, pressing or rubbing their eyes with their fingers or knuckles. Pupillary responses are usually sluggish or absent. Fundus examination may initially appear normal, but over time, various changes can develop, including a mottled or marbled appearance of the Retina, vessel attenuation, and the later appearance of Pigment clumping. Associated ocular findings can include Hyperopia, Cataract, and Keratoconus.

Causes

The disorder is almost exclusively inherited in an Autosomal recessive pattern, though rare Autosomal dominant cases have been reported. It is caused by mutations in at least 25 different genes, all critical for the development and function of the Retina. The most commonly implicated genes include RPE65, CEP290 (which is also associated with Joubert syndrome and Senior-Løken syndrome), and GUCY2D. These mutations disrupt critical pathways, such as the Visual cycle within the Retinal pigment epithelium or the phototransduction cascade in photoreceptors, leading to early and severe cell dysfunction or death.

Diagnosis

Diagnosis is based on clinical findings, family history, and specialized testing. Electroretinography is a key diagnostic tool, typically showing severely reduced or non-detectable electrical responses from both rods and cones, confirming the retinal origin. Genetic testing, often via panel sequencing or Whole exome sequencing, is essential to identify the causative mutation and inform prognosis and treatment options. Differential diagnosis involves ruling out other causes of infantile blindness, such as Achromatopsia, Retinopathy of prematurity, and structural anomalies like Optic nerve hypoplasia.

Treatment

Management is multidisciplinary, involving Low vision rehabilitation and supportive care. The landmark advancement in treatment is Gene therapy, specifically Voretigene neparvovec, marketed as Luxturna by Spark Therapeutics. This AAV-based therapy, approved by the U.S. Food and Drug Administration and the European Medicines Agency, delivers a functional copy of the RPE65 gene to retinal cells and can improve light sensitivity and functional vision in eligible patients. Other investigational therapies, including those targeting the CEP290 gene using CRISPR technology, are in clinical trials. Supportive measures include the use of Low vision aids and management of complications like Cataract.

Prognosis

The visual deficit is severe and generally stable, though progressive retinal degeneration can occur. Complete blindness is not universal, and many individuals retain some degree of light perception. The advent of Gene therapy has altered the prognosis for a subset of patients with mutations in RPE65, offering the potential for meaningful, sustained improvements in visual function. For other genetic forms, the prognosis remains one of severe, lifelong visual impairment, emphasizing the importance of early intervention and support services.

Epidemiology

Leber congenital amaurosis is a leading genetic cause of blindness in children, with an estimated prevalence between 1 in 40,000 to 1 in 100,000 live births worldwide. It accounts for approximately 10-20% of cases of congenital blindness. There is no known ethnic or gender predilection, consistent with its Autosomal recessive inheritance pattern. The condition has been documented globally, with research and clinical trials conducted at major institutions like the University of Pennsylvania and the Moorfields Eye Hospital.

Category:Genetic disorders Category:Eye diseases